IMI – Clinical Management Guidelines Report

Kate L. Gifford; Kathryn Richdale; Pauline Kang; Thomas A. Aller; Carly S. Lam; Y. Maria Liu; Langis Michaud; Jeroen Mulder; Janis B. Orr; Kathryn A. Rose; Kathryn J. Saunders; Dirk Seidel; J. Willem L. Tideman; Padmaja Sankaridurg

doi:10.1167/iovs.18-25977

IMI – Clinical Management Guidelines Report

Kate L. Gifford, Kathryn Richdale, Pauline Kang, Thomas A. Aller, Carly S. Lam, Y. Maria Liu, Langis Michaud, Jeroen Mulder, Janis B. Orr, Kathryn A. Rose, Kathryn J. Saunders, Dirk Seidel, J. Willem L. Tideman, Padmaja Sankaridurg

College of Health and Life Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Best practice clinical guidelines for myopia control involve an understanding of the epidemiology of myopia, risk factors, visual environment interventions, and optical and pharmacologic treatments, as well as skills to translate the risks and benefits of a given myopia control treatment into lay language for both the patient and their parent or caregiver. This report details evidence-based best practice management of the pre-, stable, and the progressing myope, including risk factor identification, examination, selection of treatment strategies, and guidelines for ongoing management. Practitioner considerations such as informed consent, prescribing off-label treatment, and guides for patient and parent communication are detailed. The future research directions of myopia interventions and treatments are discussed, along with the provision of clinical references, resources, and recommendations for continuing professional education in this growing area of clinical practice.

Original language	English
Article number	M184–M203
Pages (from-to)	M184-M203
Journal	Investigative Ophthalmology and Visual Science
Volume	60
Issue number	3
DOIs	https://doi.org/10.1167/iovs.18-25977
Publication status	Published - 28 Feb 2019

Bibliographical note

Keywords

Clinical considerations
Myopia control
Myopia progression
Patient communication
Practitioner education

Access to Document

10.1167/iovs.18-25977Licence: CC BY-NC-ND 3.0

IMI – Clinical Management Guidelines Report
Copyright 2019 The Authors. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
Final published version, 998 KBLicence: CC BY-NC-ND 3.0

Cite this

Gifford, K. L., Richdale, K., Kang, P., Aller, T. A., Lam, C. S., Liu, Y. M., Michaud, L., Mulder, J., Orr, J. B., Rose, K. A., Saunders, K. J., Seidel, D., Tideman, J. W. L., & Sankaridurg, P. (2019). IMI – Clinical Management Guidelines Report. Investigative Ophthalmology and Visual Science, 60(3), M184-M203. Article M184–M203. https://doi.org/10.1167/iovs.18-25977

@article{b128c9d731224777857acbf7a9583d05,

title = "IMI – Clinical Management Guidelines Report",

abstract = "Best practice clinical guidelines for myopia control involve an understanding of the epidemiology of myopia, risk factors, visual environment interventions, and optical and pharmacologic treatments, as well as skills to translate the risks and benefits of a given myopia control treatment into lay language for both the patient and their parent or caregiver. This report details evidence-based best practice management of the pre-, stable, and the progressing myope, including risk factor identification, examination, selection of treatment strategies, and guidelines for ongoing management. Practitioner considerations such as informed consent, prescribing off-label treatment, and guides for patient and parent communication are detailed. The future research directions of myopia interventions and treatments are discussed, along with the provision of clinical references, resources, and recommendations for continuing professional education in this growing area of clinical practice.",

keywords = "Clinical considerations, Myopia control, Myopia progression, Patient communication, Practitioner education",

author = "Gifford, {Kate L.} and Kathryn Richdale and Pauline Kang and Aller, {Thomas A.} and Lam, {Carly S.} and Liu, {Y. Maria} and Langis Michaud and Jeroen Mulder and Orr, {Janis B.} and Rose, {Kathryn A.} and Saunders, {Kathryn J.} and Dirk Seidel and Tideman, {J. Willem L.} and Padmaja Sankaridurg",

year = "2019",

month = feb,

day = "28",

doi = "10.1167/iovs.18-25977",

language = "English",

volume = "60",

pages = "M184--M203",

journal = "Investigative Ophthalmology and Visual Science",

issn = "1552-5783",

publisher = "Association for Research in Vision and Ophthalmology Inc.",

number = "3",

}

TY - JOUR

T1 - IMI – Clinical Management Guidelines Report

AU - Gifford, Kate L.

AU - Richdale, Kathryn

AU - Kang, Pauline

AU - Aller, Thomas A.

AU - Lam, Carly S.

AU - Liu, Y. Maria

AU - Michaud, Langis

AU - Mulder, Jeroen

AU - Orr, Janis B.

AU - Rose, Kathryn A.

AU - Saunders, Kathryn J.

AU - Seidel, Dirk

AU - Tideman, J. Willem L.

AU - Sankaridurg, Padmaja

PY - 2019/2/28

Y1 - 2019/2/28

N2 - Best practice clinical guidelines for myopia control involve an understanding of the epidemiology of myopia, risk factors, visual environment interventions, and optical and pharmacologic treatments, as well as skills to translate the risks and benefits of a given myopia control treatment into lay language for both the patient and their parent or caregiver. This report details evidence-based best practice management of the pre-, stable, and the progressing myope, including risk factor identification, examination, selection of treatment strategies, and guidelines for ongoing management. Practitioner considerations such as informed consent, prescribing off-label treatment, and guides for patient and parent communication are detailed. The future research directions of myopia interventions and treatments are discussed, along with the provision of clinical references, resources, and recommendations for continuing professional education in this growing area of clinical practice.

AB - Best practice clinical guidelines for myopia control involve an understanding of the epidemiology of myopia, risk factors, visual environment interventions, and optical and pharmacologic treatments, as well as skills to translate the risks and benefits of a given myopia control treatment into lay language for both the patient and their parent or caregiver. This report details evidence-based best practice management of the pre-, stable, and the progressing myope, including risk factor identification, examination, selection of treatment strategies, and guidelines for ongoing management. Practitioner considerations such as informed consent, prescribing off-label treatment, and guides for patient and parent communication are detailed. The future research directions of myopia interventions and treatments are discussed, along with the provision of clinical references, resources, and recommendations for continuing professional education in this growing area of clinical practice.

KW - Clinical considerations

KW - Myopia control

KW - Myopia progression

KW - Patient communication

KW - Practitioner education

UR - http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.18-25977

UR - http://www.scopus.com/inward/record.url?scp=85063402762&partnerID=8YFLogxK

U2 - 10.1167/iovs.18-25977

DO - 10.1167/iovs.18-25977

M3 - Article

SN - 1552-5783

VL - 60

SP - M184-M203

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

IS - 3

M1 - M184–M203

ER -

IMI – Clinical Management Guidelines Report

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this